•
Longevity: The Battle of Aging as Disease
Talks about Longevity, Aging and Biotechnology
JB
Justin Briggs
Venture Partner at Atento Capital
Tulsa, Oklahoma
Overview
Justin Briggs is a biotech investor, board member, and startup advisor with a focus on scaling biomedical discovery. Currently serving as an Operating Partner and Venture Partner at Prime Movers Lab, he has held various board member positions in biotech companies like LyGenesis and Gilgamesh Pharmaceuticals, showcasing his expertise in biomanufacturing and drug discovery.
Briggs has successfully navigated the biotech industry, contributing to the growth and strategic planning of companies while also investing in various sectors such as Semiconductors, Robotics, and Biotech, demonstrating a strong track record of supporting innovative startups and driving impactful investments.
Work Experience
VP Corporate Development
2024 - Current
Board Member
2023 - 2024
Zafrens is a company developing a massively parallel drug discovery platform.
Zafrens offers a throughput platform for cell characterization, correlating molecular profiles to phenotype for accelerated drug discovery.
Raised $29,000,000.00 from Prime Movers Lab, BlueYard Capital, Global Brain Corporation, Iaso Ventures, Alix Ventures, KOFA Healthcare, Possible Ventures, Hawktail Management and FoundersX Ventures.
Operating Partner
2024
Partner
2022 - 2024
Prime Movers Lab invests in breakthrough scientific startups founded by the world's prime movers – the inventors who transform billions of lives across energy, transportation, infrastructure, manufacturing, human augmentation, and agriculture. PML is actively investing out of Fund 3, an early stage fund, and has $1.2B under management. We offer Prime Movers comprehensive resources and integrated coaching to support the transformation of world-class technical experts into extraordinary executives. Our team has developed in-depth academic scientific research, commercialized novel intellectual property, scaled significant enterprises, and mentored renowned scientists on their entrepreneurial journey.
Venture Partner
2022 - 2022
Prime Movers Lab invests in startups reinventing energy, transportation, infrastructure, manufacturing, human augmentation, and agriculture.
Board Member
2023
LyGenesis is a clinical-stage startup pioneering the use of lymph nodes as living bioreactors to transform transplant medicine and expand the field of cell therapy for millions of patients.
LyGenesis is an organ regeneration company that facilitates organ regeneration and transplant.
Raised $37,000,000.00 from Juvenescence, Prime Movers Lab and Juvenescence.
Board Member
2023
Iridia is storing the world of data in physical form using nature's building block, DNA.
Iridia is a nanotechnology company that specializes in bio-chemistry, molecular biology, and DNA.
Raised $40,070,001.00 from Prime Movers Lab, North Sound Ventures, ATEM Capital Fund LP, Pritzker/Vlock Family Office, Longley Capital, JSR, LifeSci Venture Partners, Tech Coast Angels, Validus Growth Investors and Western Digital Capital.
Board Member
2023
Morphoceuticals is developing therapeutics modulating the “bio-electrome” to regrow human limbs, repair injuries, and treat rare congenital diseases and malformations based on the research of Drs. Michael Levin and David Kaplan.
Morphoceuticals is a biotechnology platform establishing a basis for limb regeneration and the discovery of regenerative interventions.
Raised $11,500,000.00 from Juvenescence and Prime Movers Lab.
Venture Partner
2022
Atento Capital is a Tulsa-based investment firm at the crossroads of entrepreneurship, economic development, finance and social improvement.
Board Member
2023 - 2024
Gilgamesh is a clinical-stage company developing safer, more beneficial molecules at the forefront of psychedelic medicine.
Board Member
2023 - 2024
IVIVA Medical was founded with the goal of developing autologous tissue constructs as a solution to end-state kidney disease (ESKD).
Board Observer
2023 - 2024
Dimension inx manufactures the substrates for life for use as tissue therapeutics, including 3D printed bone grafts, soft tissue replacements, and injectable bioscaffolds.
Dimension Inx specializes in developing regenerative microenvironments that give the body a blueprint to heal itself.
Raised $17,701,341.00 from Revolution’s Rise of the Rest Seed Fund, Portal Innovations, Alumni Ventures, Prime Movers Lab, Solas BioVentures and KdT Ventures.
Board Member
2022 - 2024
Elevian develops medicines that restore youthful regenerative capacity with the potential to treat and prevent many age-related diseases.
Raised $64,333,889.00 from Leslie Ventures, Bold Capital Partners, Prime Movers Lab and Kuelbs Family Office.
Education
Bachelor of Science (B.Sc.)
2005 - 2007
MBA
2009 - 2010
Latest Articles
•
Mito is awesome and the team is excellent!
Talks about Mito and team excellence
•
The bonkers part about your first chart, Jonathan, Is that the coinmarketcap was $3T in November…
Talks about cryptocurrency market, web3 and web2
•
Breaking the Synthesis Barrier — Postera
Talks about Machine Learning, Chemistry and Artificial Intelligence